JAK2V617F mutation is common in old patients with polycythemia vera and essential thrombocythemia

Aging Clinical and Experimental Research

Volumn 23, Issue 1, 2011, Pages 17-21

  Randi, Maria Luigia ^a   Ruzzon, Elisabetta ^a   Tezza, Fabiana ^a   Scapin, Margherita ^a   Duner, Elena ^a   Scandellari, Raffaella ^a   Fabris, Fabrizio ^a  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

Author keywords

Essential thrombocythemia; JAK2V617F; Polycythemia vera

Indexed keywords

HYDROXYUREA; JANUS KINASE 2;

ADULT; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; GENE MUTATION; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELOPROLIFERATIVE DISORDER; POLYCYTHEMIA VERA; THROMBOCYTHEMIA; THROMBOSIS; WILD TYPE;

EID: 79956299123     PISSN: 15940667     EISSN: 17208319     Source Type: Journal    
DOI: 10.1007/BF03324948     Document Type: Article

References (27)

1. Adamson JW, Fialkow PJ, Murphy S, Prchal JF, Steinmann L. Polycythemia vera: stem cell and probable clonal origin of the disease. N Engl J Med 1976; 295: 913-6.
2. Fialkow PJ, Faguet GB, Jacobson RJ, Vaidya K, Murphy S. Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. Blood 1981; 58: 916-8.
3. Levine RL, Wadleigh M, Cools J et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387-97. (Pubitemid 40544655)
4. Baxter EJ, Scott LM, Campbell PJ et al. Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-61.
5. Kralovics R, Passamonti F, Buser AS et al. A gain-of-function mutation in JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-90. (Pubitemid 40570926)
6. James C, Ugo V, Le Couedec JP et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera. Nature 2005; 434: 1144-8. (Pubitemid 40663494)
7. Zhao R, Xing S, Li Z et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 2005; 280: 22788-92. (Pubitemid 40853184)
8. Scott LM, Tong W, Levine RL et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007; 356: 459-68. (Pubitemid 46193073)
9. Campbell P, Scott LM, Buck G et al. Definition of subtypes of essential thrombocythemia and relation to polycythemia vera based on JAK2V617F mutation status: a prospective study. Lancet 2005; 366: 1945-53. (Pubitemid 41713984)
10. Cortelazzo S, Viero P, Finazzi G, D'Emilio A, Rodeghiero F, Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol 1990; 8: 556-62. (Pubitemid 20087557)
11. Finazzi G, Rambaldi A, Guerini V, Carobbio A, Barbui T. Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status. Haematologica 2007; 92: 135-6. (Pubitemid 46232672)
12. Vannucchi AM, Antonioli E, Guglielmelli P et al. Clinical profile of homozygous JAK2V617F mutation in patients with polycythemia vera and essential thrombocythemia. Blood 2007; 110: 840-6. (Pubitemid 47267419)
13. Lansdorp PM. Telomers, stem cells and hematology. Blood 2008; 111: 1759-66.
14. Alzarez-Larran A, Cervantes F, Bellosillo B et al. Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. Leukemia 2007; 21: 1218-23. (Pubitemid 46831811)
15. Finazzi G, Ruggeri M, Rodeghiero F, Barbui T. Second malignancies in patients with essential thrombocytemia treated with busulphan and hydroxyurea: long-term follow-up of a randomised clinical trial. Br J Haematol 2000; 110: 577-83.
16. Cervantes F, Passamonti F, Barosi G. Life expectancy and prognostic factors in the classic bcr/abl-negative myeloproliferative disorders. Leukemia 2008; 22: 905-14. (Pubitemid 351698623)
17. Berlin N. Diagnosis and classification of polycythemias. Semin Hematol 1978; 12: 339-51.
18. Murphy S, Peterson P, Iland H, Laszlo J. Experience of the Polycythemia Vera Study group with essential thrombocythemia: a final report on diagnostic criteria, survival and leukemic transition by treatment. Semin Hematol 1997; 34: 29-39. (Pubitemid 27063140)
19. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 292-302.
20. Passamonti F, Rumi E, Pietra D et al. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34 cells into peripheral blood in myeloproliferative disorders. Blood 2006; 107: 3676-82.
21. Lussana F, Cabrelon S, Pagani C, Kamphuisen PW, Buller HR, Cattaneo M. Associations of V167FJak2 mutation with the risk of thrombosis among patients with essential thrombocythemia or idiopathic myelofibrosis: a systemic review. Thromb Res 2009; 124: 409-17.
22. Antonioli E; Guglielmelli P, Pancrazi A et al. Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia 2005; 19: 1847-9. (Pubitemid 41486170)
23. Teofili L, Giona F, Martini M et al. The revised WHO diagnostic criteria for Ph-negative myeloproliferative diseases are not appropriate for diagnostic screening of childhood polycythemia vera and essential thrombocythemia. Blood 2007; 110: 3384-6. (Pubitemid 350106333)
24. Tefferi A, Thiele J, Orazi A et al. Proposal and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007; 110: 1092-7. (Pubitemid 47281402)
25. Lippert E, Boissinot M, Kralovics R et al. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood 2006; 108: 1865-7. (Pubitemid 44394995)
26. Beer PA, Campbell PJ, Scott LM et al. MPL mutation in myeloproliferative disorders: analysis of the PT-1 cohort. Blood 2008; 112: 141-9.
27. Girodon F, Schaeffer C, Cleyrat C et al. Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V671F-positive patients within the first years of hydroxyurea therapy. Haematologica 2008; 93: 1723-7.